Gritstone to Release First Quarter 2022 Financial Results on May 5 and Announces Q&A Opportunity for Shareholders
Gritstone bio (Nasdaq: GRTS) plans to release its financial results for Q1 2022 and provide updates on May 5, 2022. They are engaging shareholders by partnering with Say Technologies to allow question submissions, with selected inquiries answered by management on May 11, 2022. The company focuses on developing immunotherapies for cancer and infectious diseases using its Gritstone EDGE™ platform. Their lead programs include the cancer immunotherapy GRANITE and the COVID-19 vaccine CORAL, supported by collaborations with NIH and Gilead Sciences.
- Engaging shareholders through a question submission platform with Say Technologies.
- Focus on innovative immunotherapy programs, which may enhance future growth.
- Dependence on the success of ongoing clinical trials, which poses significant risks.
- Existing cash may not be sufficient for ongoing operations without additional funding.
EMERYVILLE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that it will report its financial results for the first quarter ended March 31, 2022 and provide recent clinical and corporate updates via a press release on Thursday, May 5, 2022 at 4:05pm Eastern Time (ET).
To facilitate engagement with the company's shareholder base and connections with its investors, Gritstone is partnering with Say Technologies to enable shareholders to submit and upvote questions through Say’s online portal, a selection of which will be answered by Gritstone management via a post on the IR section of the company’s website at https://ir.gritstonebio.com/investors/events.
From 9:00am ET Tuesday, May 3 through 5:00pm ET Friday, May 6, all shareholders can submit questions at the following link: http://app.saytechnologies.com/gritstone-2022-q1
Gritstone will then post a response addressing select questions after market close on Wednesday, May 11.
Shareholders can email support@saytechnologies.com for any support inquiries.
About Gritstone
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary artificial intelligence-based platform, Gritstone EDGE™, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient’s immune system to specifically attack and destroy disease-causing cells. The company’s lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an “off-the-shelf” shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a program delivering T cell enhanced self-amplifying mRNA (samRNA) vaccine candidates for COVID-19 that is supported by departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and through a license agreement with La Jolla Institute for Immunology. Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit www.gritstonebio.com.
Gritstone Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs, the advancements in Gritstone’s ongoing clinical trials and the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gritstone in general, see Gritstone’s most recent Annual Report on Form 10-K filed on March 10, 2022 and Gritstone’s future reports to be filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof. Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.
Gritstone Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
Investors:
George E. MacDougall
Director, Investor Relations & Corp Comms
Gritstone bio, Inc.
ir@gritstone.com
FAQ
What is the date for Gritstone bio's Q1 2022 financial results release?
When will Gritstone bio answer shareholder questions?
What products is Gritstone bio developing?
